How to Use Cagrilintide
Complete guide to Cagrilintide dosing, administration, timing, and protocol recommendations.
Quick Overview
Cagrilintide (also called AM833) is a long-acting synthetic analog of amylin, the gut-brain satiety hormone co-secreted with insulin by pancreatic beta cells. It is an investigational once-weekly injectable being developed by Novo Nordisk for obesity, most prominently as the amylin half of CagriSema (cagrilintide plus semaglutide). It is not yet approved as a standalone drug, but it has cleared phase 2 trials and is in late-stage development.
Dosing Guidelines
Common Dose
2.4 mg weekly
Frequency
Once weekly
Dose Range
1.0-2.4 mg weekly (dose escalation)
Note: Most effective when combined with semaglutide (CagriSema). Works through amylin pathway which is complementary to GLP-1 mechanism. Dose escalation typically used to minimize GI side effects. Not yet commercially available - still in clinical trials.
Administration Method
Subcutaneous injection once weekly
Best Time to Take
Any consistent time weekly
Once-weekly injection provides sustained amylin receptor activation. Timing is flexible but should be consistent week to week.
Protocol Duration
Long-term / chronic use expected
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Nausea (common, usually transient)
- •Vomiting
- •Diarrhea
- •Constipation
- •Abdominal pain
Frequently Asked Questions
What is the recommended dose for Cagrilintide?
2.4 mg weekly
How do you administer Cagrilintide?
Subcutaneous injection once weekly
When is the best time to take Cagrilintide?
Any consistent time weekly
How long should you use Cagrilintide?
Long-term / chronic use expected
This information is for educational purposes only. Always consult with a healthcare professional before using any peptide. Dosing information is based on research literature and community reports, not medical advice.